Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intellectual Curiosity and Action Initiation are Subtypes of Apathy Affected in Huntington Disease Gene Expansion Carriers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Astrocytic reactivity triggered by defective autophagy and metabolic failure causes neurotoxicity in frontotemporal dementia type 3

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. CCG•CGG interruptions in high-penetrance SCA8 families increase RAN translation and protein toxicity

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: The potential of neurofilament light (NfL) as a blood-based biomarker is currently being investigated in autosomal dominant neurodegenerative disease. This study explores the clinical utility of serum-NfL in frontotemporal dementia due to CHMP2B mutation (FTD-3).

METHODS: This cross-sectional study included serum and CSF data from 38 members of the Danish FTD-3 family: 12 affected CHMP2B mutation carriers, 10 presymptomatic carriers, and 16 noncarriers. Serum-NfL levels measured by single-molecule array (Simoa) technology were tested for associations with the clinical groups and clinical parameters. Serum and CSF data were compared, and CSF/serum-albumin ratio was included as a measure of blood-brain barrier (BBB) function.

RESULTS: Serum-NfL concentrations were significantly increased in symptomatic CHMP2B mutation carriers compared to presymptomatic carriers and in both groups compared to healthy family controls. Serum-NfL levels appear to increase progressively with age in presymptomatic carriers, and this is perhaps followed by a change in trajectory when patients become symptomatic. Measurements of NfL in serum and CSF were highly correlated and fold-changes in serum and CSF between clinical groups were similar. Increase in serum-NFL levels was correlated with reduced ACE-score. Higher CSF/serum-albumin ratios were demonstrated in FTD-3 patients, but this did not affect the significant associations between serum-NfL and clinical groups.

CONCLUSION: Serum-NfL could be utilized as an accurate surrogate marker of CSF levels to segregate symptomatic CHMP2B carriers, presymptomatic carriers, and non-carriers. The observed indication of BBB dysfunction in FTD-3 patients did not confound this use of serum-NfL. The results support the occurrence of mutation-related differences in NfL dynamics in familial FTD.

Original languageEnglish
JournalDementia and Geriatric Cognitive Disorders
Issue number6
Pages (from-to)533-538
Number of pages6
Publication statusPublished - 2020

Bibliographical note

© 2021 S. Karger AG, Basel.

ID: 68397146